Securities Code: 000931
Securities Abbreviation: Zhongguancun
Announcement No.: 2026-054
Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd.
Announcement on Duoduo Pharmaceutical's Ivabradine Hydrochloride Tablets Receiving Acceptance Notice from the National Medical Products Administration
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false representations, misleading statements, or material omissions.
Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. (hereinafter referred to as the "Company")'s subsidiary, Duoduo Pharmaceutical Co., Ltd. (hereinafter referred to as "Duoduo Pharmaceutical"), recently received an "Acceptance Notice" issued by the National Medical Products Administration (hereinafter referred to as "NMPA"). The marketing authorization application for Ivabradine Hydrochloride Tablets (Specification: 5mg (calculated as C27H36N2O5)) has been acc